Home > Oncology > ASCO 2019 > Lung Cancer > Lurbinectedin shows promise as second-line therapy for SCLC

Lurbinectedin shows promise as second-line therapy for SCLC

Presented By
Dr Luis G. Paz-Ares, Hospital Universitario 12 de Octubre, Spain
Conference
ASCO 2019
Medical writer: Tim Donald, ELS Lurbinectedin, an inhibitor of activated transcription, showed notable anti-tumour activity as a second-line treatment in small cell lung cancer (SCLC) in a phase II clinical trial, according to a June 1 presentation (Abstract 8506). “Lurbinectedin is an active single agent in second-line SCLC,” said presenter Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, CNIO, and Universidad Complutense and Ciberonc, Spain. “Anti-tumour activity has been observed in sensitive patients, with an overall response rate [ORR] of 45%. But also, in a setting where we have very few opportunities for treatment, in the setting of resistance, with ORR of 22.2%.” In addition, the safety profile was favorable, and side effects were easily managed, he said. There were low percentages of treatment-related serious adverse events (SAEs) and of discontinuation due to adverse events (AEs), and there were no toxic deaths. “W...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on